| NCT06925542 | A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease | RECRUITING | PHASE1 | 2025-03-10 | 2031-12-31 | 2031-12-31 |
| NCT06492304 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | RECRUITING | PHASE1, PHASE2 | 2024-08-13 | 2030-11 | 2030-05 |
| NCT05795595 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | RECRUITING | PHASE1, PHASE2 | 2023-03-13 | 2030-05 | 2030-04 |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | RECRUITING | PHASE1, PHASE2 | 2023-03-10 | 2030-02 | 2030-01 |
| NCT05565248 | An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D | RECRUITING | PHASE1, PHASE2 | 2023-01-20 | 2025-08 | 2025-04 |
| NCT05210530 | An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D | COMPLETED | PHASE1 | 2022-01-24 | 2023-01-19 | 2023-01-19 |
| NCT04502446 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) | TERMINATED | PHASE1 | 2020-07-31 | 2024-08-30 | 2024-08-30 |
| NCT04438083 | A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) | TERMINATED | PHASE1 | 2020-06-16 | 2024-10-08 | 2024-10-08 |
| NCT04244656 | A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma | TERMINATED | PHASE1 | 2020-01-22 | 2024-01-04 | 2024-01-04 |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) | TERMINATED | PHASE1, PHASE2 | 2019-07-22 | 2024-10-04 | 2024-10-04 |